Question 1

What is synbiointel.com?

Accepted Answer

synbiointel.com is the leading intelligence platform for the synthetic biology industry — a Bloomberg Terminal-style dashboard covering platform specifications, company profiles, funding rounds, FDA regulatory pipeline, clinical trials, precision fermentation scale-up, AI+biology convergence, and breaking news across every major synbio company globally. It is updated hourly by an autonomous AI agent.

Question 2

Which synthetic biology companies does synbiointel.com track?

Accepted Answer

synbiointel.com tracks all major synthetic biology companies including Ginkgo Bioworks, Twist Bioscience, Absci, Recursion Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, Verve Therapeutics, EvolutionaryScale, Perfect Day, Solugen, LanzaTech, Pivot Bio, Benchling, Mammoth Biosciences, and dozens more across therapeutics, fermentation, agriculture, AI+bio, and tools.

Question 3

What are the major synthetic biology platform types in 2026?

Accepted Answer

The major synbio platform types in 2026 include Cell Programming platforms (Ginkgo, Zymergen legacy, Amyris legacy), Protein Design platforms (EvolutionaryScale, Absci, Generate Bio, Cradle), Precision Fermentation platforms (Perfect Day, Solugen, LanzaTech), Gene Editing platforms (CRISPR Therapeutics, Beam, Intellia, Mammoth), DNA Synthesis platforms (Twist, DNA Script), and Lab Automation platforms (Synthace, Strateos, Benchling).

Question 4

How much has been invested in synthetic biology?

Accepted Answer

The synthetic biology sector attracted approximately $17.3B in venture capital in 2025, with cumulative investment exceeding $70B since 2015. Major funding rounds include Recursion $500M, EvolutionaryScale $540M, Absci $200M, Solugen $400M, and Generate Bio $370M. Key investors include ARCH Venture Partners, Flagship Pioneering, DCVC, Lux Capital, Khosla Ventures, and a16z Bio.

Question 5

What is CRISPR and why does it matter for synbio?

Accepted Answer

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing technology that allows precise modification of DNA sequences. It is foundational to modern synthetic biology, enabling everything from cell therapies (Casgevy for sickle cell disease, the first approved CRISPR therapy) to crop engineering, industrial biotech, and protein design. Companies like CRISPR Therapeutics, Beam Therapeutics, Intellia, Caribou, and Mammoth Biosciences are building platforms around CRISPR-based editing.

Question 6

Which synbio therapies have received FDA approval?

Accepted Answer

As of early 2026, Casgevy (CRISPR Therapeutics/Vertex) became the first CRISPR-based gene therapy approved by the FDA in December 2023 for sickle cell disease and transfusion-dependent beta thalassemia. Multiple CAR-T cell therapies are approved including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti. Beam Therapeutics, Intellia, Verve, and Caribou have multiple candidates in clinical trials.

Question 7

How often is data on synbiointel.com updated?

Accepted Answer

synbiointel.com's news feed is updated hourly by an autonomous AI agent that scans synthetic biology industry RSS feeds and news sources. The platform database, funding tracker, clinical pipeline, and company directory are updated regularly as new data becomes available. The site deploys automatically to Cloudflare's global edge network on every update.

Question 8

What is precision fermentation and why is it important?

Accepted Answer

Precision fermentation uses engineered microorganisms (yeast, bacteria, fungi) to produce specific proteins, fats, and other molecules traditionally derived from animals or petrochemistry. Companies like Perfect Day (dairy proteins), Solugen (industrial chemicals), LanzaTech (carbon capture to ethanol), and MycoWorks (mycelium materials) are scaling this approach. The key challenge is COGS (cost of goods sold) — achieving price parity with conventional production at commercial scale.

Platform	Company	Type	Chassis	Vertical	Stage	Funding
Ginkgo Bioworks	Ginkgo Bioworks	cell-programming	Multiple (yeast, E. coli, mammalian)	tools	commercial	$2.8B+
Twist Bioscience	Twist Bioscience	dna-synthesis	N/A (DNA manufacturer)	tools	commercial	$900M+
Mammoth Biosciences	Mammoth Biosciences	gene-editing	Multiple	therapeutics	clinical	$600M+
ArsenalBio	ArsenalBio	cell-therapy	Human T cells	therapeutics	clinical	$830M+
EvolutionaryScale	EvolutionaryScale	ai-protein-design	N/A (computational)	tools	growth	$142M+

Company	Round	Amount	Lead Investor	Date
Cradle	Series B	$73M	Index Ventures	Sep 9, 2024
EvolutionaryScale	Seed	$142M	Nat Friedman	Jun 24, 2024
Aleph Farms	Series C	$105M	L Catterton	May 7, 2024
Tune Therapeutics	Series B	$175M	ARCH Venture Partners	Mar 11, 2024
ArsenalBio	Series C	$630M	Westlake Village BioPartners	Jan 17, 2024

Absci Trades at $2.86 Ahead of Critical Q4 Earnings